<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872079</url>
  </required_header>
  <id_info>
    <org_study_id>CAMM-04-07S</org_study_id>
    <nct_id>NCT00872079</nct_id>
  </id_info>
  <brief_title>Personalized Warfarin Dosing by Genomics and Computational Intelligence</brief_title>
  <official_title>Personalized Warfarin Dosing Using Genomics and Computational Intelligence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will create a computer program that can be used to help dose a drug called&#xD;
      warfarin for the prevention of blood clotting. The study will collected specific information&#xD;
      about those patients receiving this drug and use that information to create a computer&#xD;
      program that will predict the effects of the drug. With this prediction program in place, the&#xD;
      investigators can perform a series of &quot;what if I gave this amount of drug&quot; simulations to&#xD;
      determine the best dose of drug for that patient. Once the computer programs are developed,&#xD;
      the investigators will test the program in patients that actually need this drug. They will&#xD;
      also include genetic information into the prediction since it has been shown that this&#xD;
      information can affect how well the drug works. Patients will have this genetic information&#xD;
      determined during this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this project is to develop new techniques to incorporate genomic data into&#xD;
      pharmacodynamic models to improve the dosing of chronically administered drugs. Specifically,&#xD;
      the investigators look to improve warfarin therapy by decreasing the variability in the&#xD;
      effect of this drug using information about the subjects genotype and computational&#xD;
      intelligence. The investigators propose to achieve our objectives using a prospective,&#xD;
      randomized, controlled clinical trial of a computer program that they will develop from both&#xD;
      historical and prospective data. This computer program will be tested against a control group&#xD;
      using standard warfarin dosing, and a group using standard dosing plus subject genotype.&#xD;
      Warfarin dose and response data will be obtained from patients seen in the Louisville VA&#xD;
      anticoagulation clinic. Following informed consent, subject genotype for cytochrome P450&#xD;
      allele 2C9 (2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) will be&#xD;
      determined. Other data routinely obtained to aid in warfarin dosing will also be recorded.&#xD;
      Using this information, the investigators will develop many different models for warfarin&#xD;
      dosing using incrementally more information. Each of these models will be tested using&#xD;
      computer simulation until they have obtained the best model. This model will be used in a&#xD;
      pilot study to test performance in real time. The results of the pilot study will then be&#xD;
      used to power a final clinical trial of standard dosing, standard dosing and genetic&#xD;
      information, computer dosing, and computer dosing plus genetic information.&#xD;
&#xD;
      The specific aims of this research are:&#xD;
&#xD;
        1. Determine the structure and the type of neural network model for predictions from&#xD;
           historically obtained data. (Computer Model)&#xD;
&#xD;
        2. Prospectively develop an individualized neural network and nonlinear mixed effect&#xD;
           modelling (NONMEM) model capable of predicting erythropoietin dosing for chronic&#xD;
           in-center hemodialysis patients using adaptive techniques.&#xD;
&#xD;
        3. Develop computer programs based on neural computing that can be used in a clinical&#xD;
           setting. (Computer Model)&#xD;
&#xD;
        4. Determine the utility of the computer programs prospectively in the clinical setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Funding&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Genomics</measure>
    <time_frame>Baseline</time_frame>
    <description>During Aim 2, Determined Patient Genotypes: CYP2C9 and VKORC1.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Genomics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.&#xD;
Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genomics</intervention_name>
    <description>Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.</description>
    <arm_group_label>Genomics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Warfarin therapy&#xD;
&#xD;
          -  Attend anticoagulation clinic&#xD;
&#xD;
          -  Warfarin therapy for 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E. Brier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <results_first_submitted>February 21, 2014</results_first_submitted>
  <results_first_submitted_qc>February 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2014</results_first_posted>
  <last_update_submitted>February 21, 2014</last_update_submitted>
  <last_update_submitted_qc>February 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>warfarin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were not enrolled into the randomized clinical trial for Aim 4 due to lack of funding.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Genomics</title>
          <description>Model Predictive Control: Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an INR value within a specific target range.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Genomics</title>
          <description>The specific aims of this research are:&#xD;
Determine the structure and the type of neural network model for predictions from historically obtained data. (Computer Model)&#xD;
Prospectively develop an individualized neural network and NONMEM model capable of predicting erythropoietin dosing for chronic in-center hemodialysis patients using adaptive techniques.&#xD;
Develop computer programs based on neural computing that can be used in a clinical setting. (Computer Model)&#xD;
Determine the utility of the computer programs prospectively in the clinical setting.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Genomics</title>
        <description>During Aim 2, Determined Patient Genotypes: CYP2C9 and VKORC1.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Genomics</title>
            <description>Model Predictive Control: Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an INR value within a specific target range.&#xD;
There are 4 Aims in this study.&#xD;
To collect historical data on warfarin dosing in subjects.&#xD;
To collect genotype information on up to 300 subjects receiving warfarin anticoagulation.&#xD;
to develop a computer model incorporating the information from aim 1 and aim 2.&#xD;
To conduct a randomized clinical trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Genomics</title>
          <description>During Aim 2, Determined Patient Genotypes: CYP2C9 and VKORC1.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CYP2C9: *1/*1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: *1/*2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: *1/*3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: *2/*2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: *2/*3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: *3/*3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CYP2C9: Not Determined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VKORC1: AA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VKORCI:GA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VKORCI:GG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VKORCI: Not Determined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Genomics</title>
          <description>Model Predictive Control: Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an INR value within a specific target range.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Brier</name_or_title>
      <organization>University of Louisville</organization>
      <phone>502-852-0246</phone>
      <email>mbrier@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

